(PharmaNewsWire.Com, May 26, 2017 ) Market Data Forecast has published a new report Europe Liquid Biopsy Market, according to which the market is estimated at $135.75 million in 2016 and poised to grow $358.69 million by 2021 with a CAGR of 21.45% in the forecast period.
Technological advances over the past two decades have improved the treatment of cancer patient owing to liquid biopsy. Liquid biopsies also present with a unique opportunity to move forward with the understanding of metastatic disease development, especially to identify the pathways involved in cell invasiveness and metastatic competence.
Europe is leading market for Liquid Biopsy. Liquid biopsy market is soaring high as colorectal cancer is one of the most common cancers diagnosed in European region. There is a lot of research going on for the detection of colorectal cancer. Liquid biopsy is more effective than tissue biopsy as they can be performed with less complication and in an easy manner and they provide more accurate results
The report provides a detailed analysis of drivers and constraints that controls growth of the market. Some of the drivers are: • Increasing geriatric population. • Recent Technological advancements. • Increasing funding by government and private organizations.
For better understanding Liquid Biopsy Market is segmented by cancer type, sample type diagnosis approach and end-user. Each sub segment is accompanied with Market Size Estimations and Y-o-Y Forecasts as well.
The liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumor cells (CTC), Circulating Tumor DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.
Geographically, the market is segmented into, Spain, Germany, France, Italy and UK.U.K leads the market in this region with the rising cases of lung cancer.
The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Biocartis, Exosome Sciences, and HansaBiomed OU.Biocart is the first company to launch a fully automated liquid biopsy assay.
The Europe Liquid Biopsy Market report offers wide-range of scope:
• Regional and country-level analysis that provides an individual perspective of European region and the aforementioned countries
• Know more about key areas of industry growth via detailed Segment-level analysis on basis of cancer type, sample type, diagnosis approach and end-user along with market size forecasts and y-o-y estimations
• Detailed explanation of major drivers, restraints, opportunities, and challenges (DROC) that affect the market and impact the ever-shifting market dynamics
• Strategic Analyses containing PESTLE and Porter’s Five Forces Analyses which are obtained by studying the macro & micro environmental factors that affect the market demographics
• Comprehensive listing of key market players along with Company overview, product portfolios, financials (subjected to availability), SWOT analysis and analyst overview
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Market Outlook - Investment opportunities devised by stand in experts to provide both individuals and organizations a strong financial foothold in the market.
Check out other related studies in the Diagnostic Segment:
About us Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing an appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organization that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
